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Natural products comprise a diverse array of molecules, many
of which are biologically active. Most natural products are de-
rived from combinations of polyketides, peptides, sugars, and
fatty-acid building blocks. Peptidic macrocycles have attracted
attention as potential therapeutics possessing cell permeability,
stability, and easy-to-control variability. Here, we show that en-
zymes from the patellamide biosynthetic pathway can be har-
nessed to make macrocycles that are hybrids of amino acids
and a variety of manmade chemical building blocks, including
aryl rings, polyethers, and alkyl chains. We have made macro-
cycles with only three amino acids, one of which can be con-
verted to a thiazoline or a thiazole ring. We report the synthe-
sis of 18 peptide hybrid macrocycles, nine of which have been
isolated and fully characterized.
Natural products, in particular secondary metabolites, derived
from various natural resources such as bacteria, fungi, marine
sources, and plants, have been used as medicines since ancient
times. Today they have utility directly as drugs, for example pa-
clitaxel, or as active scaffolds, for example the b-lactam ring.[1]
The advent of high-throughput combinatorial chemistry has
coincided with a decline in attention towards natural products
by pharmaceutical companies.[2] Recent progress in phenotypic
screening and metabolomic technologies has rekindled inter-
est in natural products.[1a,2–3] In addition to vast structural and
chemical diversity, natural products are often stereochemically
complex; this feature has allowed them to evolve both specif-
icity and potency.[4] Macrocycles, in particular, whether peptidic
or polyketides, are especially appealing, owing to their inher-
ent chemical stability and structural rigidity,[5] the later proper-
ty reducing the entropic penalty for binding, thus raising
affinity.
Several natural macrocycles possess useful biological and
medicinal activities.[6] Hybrid peptide macrocycles show in-
creased chemical and structural diversity, for example, larga-
zole (PKS/NRPS hybrid), zizyphines (cyclopeptide alkaloids),
and maytansin (macrolide)[6c, 7] (Figure 1). A drawback of pepti-
dic macrocycles is their polarity, both in the side chain and the
backbone, where it is an inescapable consequence of the pep-
tide bond. High polarity hinders transport across lipid bilay-
ers;[8] strategies such as methylation, prenylation, and hetero-
cyclization aim to overcome these problems.[9] The synthesis of
macrocyclic compounds where the backbone is a hybrid of
both peptidic and non-peptidic scaffolds is desirable, as it per-
mits diversification and exquisite control of the physicochemi-
cal properties.[10]
PatGmac, the macrocyclization domain of PatG from the bio-
synthetic pathway of patellamides,[12] recognizes octapeptides
containing a thiazoline ring at the C-terminal adopting a cis
conformation followed by the recognition sequence
AYD(GE).[12b] PatGmac is as a versatile tool capable of tolerating
a range of different precursor peptides;[11,13] a proline can re-
place the thiazoline ring,[11,13a] the amino acids of the core pep-
tide are variable almost at will,[11,13] PatGmac has been reported
to make macrocycles of up to 22 amino acids,[13b] and can tol-
erate non-natural amino acids and triazole amide bond mim-
ics.[11a,13a] In an elegant paper by Schmidt and co-workers,[11b]
the chemistry of the N-terminus of the core peptide was exten-
Figure 1. Structures of hybrid molecules. A) Natural hybrid macrocyclic com-
pounds.[6c, 7] B) Hybrid cyclopeptides previously synthesized using PatG-
mac.[11] C:L indicates the ratio of the enzymatic macrocyclization product to
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sively evaluated to study the cyclization patterns of lysine and
its analogues. Depending on the length of the sequence and
the amino acid side chain, both backbone and side-chain cycli-
zation were observed along with a linear product. The synthet-
ic utility of PatGmac derives precisely from its promiscuity to-
wards the core sequence. The cyclic dehydratases, PatD and
LynD, which make thiazoline and oxazoline rings from cysteine
and serine (threonine), respectively, have also been shown to
tolerate the presence of non-natural amino acids,[13a] but it is
not known how they tolerate non-amino acid groups. Here, we
have used enzymes from cyanobactin biosynthesis to generate
eighteen hybrid peptidic/non-peptidic macrocycles that ex-
plore a wide range of chemical variation. Nine of these macro-
cycles (1–6,7a–c, Figure 2) were made at sufficient scale to
allow full characterization.
Nineteen analogues (8–26) were synthesized based on
a common precursor peptide VGAGIGFP, in which one or more
amino acids were substituted with non-natural, non-amino-
acid scaffolds. All but one of the substrates finished with a Pro
in the core peptide (one had a Cys) and all possessed a C-ter-
minal AYD, the minimal recognition sequence for PatGmac, or
AYD-Doc (8-amino-3,6-dioxaoctanoic acid; Table 1). Peptides 8–
10 contain a one-residue substitution involving small non-nat-
ural amino acids b-Ala, GABA, and Doc (8-amino-3,6-dioxaocta-
noic acid), respectively. Peptide 11 has an N-Me amino acid.
Peptides 12–18 contain either an isomer of amino benzoic
acid (Abz) at different positions or a ribose-derived sugar
amino acid (Rib). Finally, peptides 19–26 represent the hybrid
peptides, where a polyketide chain 7-aminoheptanoic acid
(7Ahp), 8-aminooctanoic acid (8Aoc), or a polyether amino acid
(PEG)4 is introduced at different positions of the peptide. Pep-
tide 26 has a Cys, which requires a heterocyclization reaction
prior to macrocylization. The peptides were all synthesized
through solid-phase peptide synthesis by using the Fmoc strat-
egy and commercially available reagents (see the Supporting
Information). The fully protected Fmoc–sugar amino acid 27
was synthesized in a similar approach to the one reported in
the literature[14] for the synthesis of the Boc-protected ana-
logue starting from d-ribose. Minor changes, such as the use
of benzyl ester protection in the synthesis, were required to
produce the desired compound 27 in good yields (see
Scheme 1 and the Supporting Information). The azide of com-
pound 28 was selectively reduced under the Staudinger reac-
tion conditions to afford the corresponding amine, which was
immediately Fmoc protected to yield 29. Benzyl deprotec-
tion[15] gave 27 in 62% yield. Compound 27 was used for pep-
tide synthesis, and deprotection of the alcohols was accom-
plished during the final acidic cleavage of the peptide.
Substrates 12–26 were purified before reaction with the en-
zyme(s), and substrates 8–11 were used without any further
purification after cleavage from the resin.
Figure 2. Structures of fully characterized macrocycles 1–6, 7a–c.
Table 1. Synthetic hybrid precursor peptides and their corresponding
PatGmac macrocyclization products.
Peptide Sequence[a] Product[b] Macrocycle[c]
8 VGA-b-Ala-IGWPAYD-Doc C
9 VGA-GABA-IGWPAYD-Doc C
10 VGA-Doc-IGWPAYD-Doc C
11 VG(N-Me)AGIGWPAYD-Doc C 1
12 VGA-2-Abz-IGFPAYD C
13 VGA-3-Abz-IGFPAYD C
14 VGA-4-Abz-IGFPAYD C 2
15 VGAG-2-Abz-GFPAYD C
16 VGAG-3-Abz-GFPAYD C 3
17 VGAG-4-Abz-GFPAYD C
18 VGA-Rib-IGFPAYD C 4
19 8Aoc-AGIGFPAYD L
20 V-7Ahp-GAGFPAYD C
21 VGAG-7Ahp-PAYD NR
22 VGAG-8Aoc-FPAYD C
23 V-8Aoc-FPAYD L
24 V-8Aoc-8Aoc-FPAYD C 5
25 V-(PEG)4-FPAYD C 6
26 V-(PEG)4-FCAYD C 7
[a] Highlighted is the minimal recognition sequence where the peptide is
cleaved. Non-natural scaffolds in the sequence are in bold. [b] All success-
ful enzymatic reactions afforded exclusively either cyclic or linear prod-
ucts, as detailed. Doc=8-amino-3,6-dioxaoctanoic acid; GABA=g-amino-
butyric acid; Abz=aminobenzoic acid; Rib= ribose sugar amino acid;
8Aoc=8-aminooctanoic acid; 7Ahp=7-aminoheptanoic acid, PEG=poly-
ethylene glycol ; C=macrocyclic ; L= linear; NR=no reaction. [c] The cor-
responding isolated macrocycle number.
Scheme 1. Synthesis of ribose sugar amino acid derivative 27. Reagents and
conditions: a) Ph3P, THF/H2O, rt, O/N (i) ; FmocOSu, DIEA, CH2Cl2, rt, O/N,
56% (ii) ; b) Et3SiH, Pd/C, MeOH, rt, 10 min, 60%.
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The macrocylization reactions were set up on small scale
(<1 mL reactions) with PatGmac in bicine buffer at pH 8.1 and
37 8C. The reactions were followed by MALDI-MS to monitor
progress. MS–MS fragmentation data established the structure
of the different products with the presence of the PV dipeptide
fragment being indicative of macrocycle formation. Table 1
summarizes the results of the reactions; in brief, only peptide
21 gave no reaction, whereas 20 and 23 yielded a linear
cleaved product. The reaction rate for these transformations
was still slow, with reaction times ranging between 2–4 weeks.
Nine representative cyclic hybrid peptides (1–6, 7a–c ;
Figure 2), products of peptides 11, 14, 16, 18, 24, 25, and 26,
were purified from a large-scale reaction and fully character-
ized by using NMR spectroscopy. One of the products of pep-
tide 26 (7a) was subsequently oxidized.
Substrates with b-Ala and GABA (8, 9) processed essentially
as native peptides, perhaps unsurprisingly because these are
very similar to amino acids. More interestingly, a longer chain
in that position, namely Doc (10), also gave only the macrocy-
cle. The inclusion of a N-methylated amino acid in peptide 11
proceeded to afford the corresponding macrocycle 1. The in-
corporation of a rigid aromatic scaffold, 2-, 3-, or 4-aminoben-
zoic acid at either position 4 or 5 of the core peptide (12–17),
proceeded normally. Remarkably, the presence of a sugar
amino acid (Rib, 18), known to cause conformational restraints
in peptidic analogues,[16] afforded exclusively the macrocyclic
product 4.
Schmidt and co-workers have previously shown the toler-
ance of PatGmac for polyketide-like scaffolds such as alkyl
chains as part of the core peptide.[11b] Peptide 19, having a N-
terminal 8Aoc unit, gave only linear peptide, whereas 20,
which has a N-terminal Val preceding the alkyl chain of 7Ahp,
yielded exclusively the cyclic product. Comparing substrates
19 and 20 indicated that an amino acid at the N-terminus was
important with our sequence for efficient macrocyclization
(Table 1). Schmidt and co-workers,[11b] showed both cyclic and
linear products were obtained with an N-terminal amino-alkyl
chain of a different peptidic sequence (Figure 1). Peptide 21
with the 7Ahp chain immediately before the required Pro in
the core peptide failed to react, but when a Phe was intro-
duced in between 8Aoc and Pro (22), the macrocycle was ob-
tained. It seems that an additional amino acid is required N-ad-
jacent to the terminal Pro or thiazoline of the core peptide for
it to be processed by the enzyme (see Table 1 and the Sup-
porting Information).
We observed a length requirement for the macrocyclization
reaction. Compound 23, which has an 8Aoc unit between a N-
terminal Val and the Phe–Pro at the C-terminus, gave only
a linear product, whereas 24 with two molecules of 8Aoc,
yielded only macrocycle 5. Substrate 25 was designed with
a pegylated chain (PEG)4 and yielded the corresponding mac-
rocycle 6. Full conversion of substrates 25 and 26 was difficult
to achieve, even after long incubation times (4 weeks, adding
more enzyme), reaching only to about 70% conversion to
macrocycle (the remainder was unreacted starting material). In
26, the Pro was replaced with a Cys, which was converted to
thiazoline with the engineered LynD enzyme[17] (establishing
this enzyme tolerated PEG) and subsequently macrocyclized to
7 (Scheme 2).
Compounds 1 and 2 were present as a single conformer,
whereas compounds 3–6 were all present as a mixture of two
conformers in approximately 2:1 (3, 4) or 3:2 (5, 6) ratios, as
confirmed by exchange spectroscopy (EXSY) experiments (see
the Supporting Information). Compound 7, containing the thia-
zoline ring, shows two separable peaks in the HPLC spectrum,
in an 8:2 (7a/7b) ratio. Both compounds have identical HRMS
and MS–MS fragmentation data. The NMR spectra of these two
compounds are, nonetheless, different, but confirm the same
peptidic sequence [cyclic V(PEG)4FThz] ; however, an EXSY ex-
periment showed no exchange. We postulate that 7a and 7b
are epimers. As thiazoline with the natural (R)l-configuration is
a substrate for the oxidase enzyme,[12d] 7a and 7b were incu-
bated in the presence of this enzyme overnight. 7a afforded
compound 7c, which was isolated, purified, and characterized
by NMR as the thiazole, confirming the oxidase enzyme also
tolerates non-peptide groups (Scheme 2). 7b was, however,
not enzymatically oxidized. We suggest the thiazoline stereo-
center of 7a is (R)l, whereas it has inverted to a (S)d-configu-
ration in 7b. This has precedent; the thiazoline moiety of pi-
peridine thiopeptides is known to be spontaneously epimer-
ized from the (R)l- to the (S)d-configuration.[18]
Natural peptide hybrid macrocycles have interesting and
useful biological properties,[6c] but are, of course, limited to
natural building blocks. The routine synthesis of macrocycles
composed of peptide and non-peptide building blocks has
wide potential in medicinal chemistry, allowing access to novel
scaffolds and the fine-tuning of properties. The patellamide
biosynthetic pathway has enzymes that catalyze a number of
valuable chemical reactions including heterocylization, oxida-
tion, and macrocyclization. The enzymes in the pathway largely
separate recognition from catalysis, and are thus assumed to
have a high degree of promiscuity.[12c] We have used these en-
zymes to synthesize diverse macrocycles containing methylat-
Scheme 2. General reaction scheme of the enzymatic transformations.
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ed amide, sugars, non-natural amino acids, aromatic rings, thia-
zole, thiazoline, polyether moieties, and polyketide-like chains.
The overall yield of the enzymatic processes (starting from sub-
strate) varied from 27 to 66% (Table S2). More interestingly, the
enzymes can synthesize a product with just three amino acids.
Thus, we have established that these enzymes are tools that,
when combined with chemical synthesis of substrates, can
produce highly modified, complex, and diverse peptide/non-
peptide hybrid macrocycles.
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